Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06441630

A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B

The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Essential Hypertension Cardiovascular Diseases Hypertension Vascular Diseases

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Gangnam CHA Medical Center

Seoul, South Korea

Location status: Recruiting

About this study

Essential Hypertension

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed informed consent
  • Patients with Essential Hypertension
  • Other inclusions applied

Exclusion criteria

  • Patient with Secondary Hypertension
  • Other exclusions applied

Treatment and study plan

AD-227A

Drug

Per Oral, 1 Tablet, Once a day for 8 weeks

AD-227B

Drug

Per Oral, 1 Tablet, Once a day for 8 weeks

AD-227C

Drug

Per Oral, 1 Tablet, Once a day for 8 weeks

Placebo of AD-227B

Drug

Per Oral, 1 Tablet, Once a day for 8 weeks

Placebo of AD-227C

Drug

Per Oral, 1 Tablet, Once a day for 8 weeks

Primary outcomes

  1. Change in MSSBP

    Time frame: Baseline to Week8

    Change from Baseline in Mean Sitting Systolic Blood Pressure

Study contacts

Contact information is provided by the study sponsor or research team.

JeongEun Park

CONTACT

[email protected]

+82-31-891-6989

Sponsors and collaborators

Lead sponsor

Addpharma Inc.

Industry

Registry information

Official study title

A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AD-227A and AD-227B Combination Treatment in Patients with Essential Hypertension

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jun 4, 2024
Registry last updated
Feb 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.